Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)

Clinical trial NCT06050694 · RECRUITING

Trial details

NCT number

NCT06050694

Sponsor

University Health Network, Toronto

Status

RECRUITING

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2025-01-24

Primary completion

2027-11-01

Enrollment

40

View on ClinicalTrials.gov